Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;20(3):187-94.
doi: 10.1016/j.jsps.2011.12.006. Epub 2011 Dec 24.

The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations

Sinaa A Al Aqeel  1 , Mohammed Al-Sultan
Affiliations

The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations

Sinaa A Al Aqeel et al. Saudi Pharm J. 2012 Jul.

Abstract

In pharmacoeconomics the costs and consequences of alternative medications are compared. Many countries have begun to use pharmacoeconomic evidence to support decisions on licensing, pricing, reimbursement, or addition to the formulary. In Saudi Arabia, it is not mandatory to submit cost effectiveness evidence to support licensing or addition to the formulary decisions however, data will be considered if submitted. Previous evidence suggests that the use of pharmacoeconomic evidence by Saudi Pharmacy and Therapeutic (P&T) committee members in formulary decisions making process is limited mainly because of lack of expertise and lack of resources. This paper intended to provide Saudi P&T decision makers with a clear set of best practice methodological recommendations to help in increasing the utilisation of pharmacoeconomic evidence in the formulary decisions making process.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incremental cost-effectiveness plane for treatment A versus B.
See this image and copyright information in PMC

References

    1. Ali M., White J., Lee C.H., Palmer J.L., Smith-palmer J., Fakhoury W., Valentine W.J. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J. Med. Econ. 2008;11(4):651–670. - PubMed
    1. Alsultan M. The role of pharmacoeconomics in formulary decision making in different Hospitals in Riyadh, Saudi Arabia. Saudi Pharm. J. 2011;19(1):51–56. - PMC - PubMed
    1. American Society of Health-System Pharmacists (ASHP) Statement on the pharmacy and therapeutics committee and the formulary system. Am. J. Hosp. Pharm. 2008;65:2384–2386. - PubMed
    1. Arnold D., Girling A., Stevens A., Liliford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009:339. b2688. - PubMed
    1. Barbieri M., Drummond M.F., Willke R. Variability in cost effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health. 2005;8:10–23. - PubMed

LinkOut - more resources